American Society of Hematology

SHERPA: Blue

People

  1. Owens
    Owens
  2. Seshan
    Seshan
  3. Zelenetz
    Zelenetz
  4. Batlevi
    Batlevi
  5. Kumar
    Kumar
  6. Matasar
    Matasar
  7. Noy
    Noy
  8. Palomba
    Palomba
  9. Caron
    Caron
  10. Hamilton
    Hamilton

Groups

  1. Biostatistics Service (11)
  2. Center for Hematologic Malignancies (11)
  3. Center for Pancreatic Cancer Research (11)
  4. Department of Medicine (11)
  5. Epidemiology and Biostatistics (11)
  6. Hematologic Malignancies, Division of (11)
  7. Lymphoma (11)
  8. Survivorship Research (10)
  9. Executive Committee, Center for Hematologic Malignancies (9)
  10. CTCR Scholars (6)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "Colette Owens"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Biostatistics Service (11)
  2. Center for Hematologic Malignancies (11)
  3. Center for Pancreatic Cancer Research (11)
  4. Department of Medicine (11)
  5. Epidemiology and Biostatistics (11)
  6. Hematologic Malignancies, Division of (11)

More Groups

People
  1. Colette Owens (11)
  2. Venkatraman Seshan (11)
  3. Andrew Zelenetz (10)
  4. Ahmet Dogan (9)
  5. Anita Kumar (9)
  6. Connie Batlevi (9)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (4)
  4. 2020 (2)
  5. 2019 (1)
Publications
  1. Blood (9)
  2. Blood Advances (2)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Journal Article

    Qualls, D.; Lam, H. Y.; Whiting, K.; Kumar, A.; Matasar, M.; Owens, C.; Nichols, C.; Espeleta, J. A.; Qiu, A.; Subzwari, S.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save